TGF-Beta: a Master Switch in Tumor Immunity
The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Abstract
The capacity of the immune system to distinguish foreign from self-antigen, and to subsequently eliminate the threat of disease without injuring the host is crucial for survival. It also serves to defend against tumor formation and progression via a process termed cancer immunosurveillance. Innate and adaptive immune cell types and effector molecules collectively function as extrinsic tumorsuppressor mechanisms. However, tumors may escape immunesurveillance through a variety of mechanisms that create a local microenvironment that is unfavorable for effective tumor immunity. Transforming growth factor β (TGF-β) has pleiotropic effects on the immune system, and is recognized as one of the most potent immunosuppressive agents in facilitating oncogenesis. The TGF-β pathway promotes cancer progression by concomitantly enhancing tumor metastases while inhibiting the protective host immunity. In this review, we discuss mechanisms through which TGF-β interferes with the development of an anti-tumor immunity and potential means through which to circumvent its activity in order to define more effective cancer immunotherapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TGFβ is a key suppressive cytokine normally produced by immune cells but which can be co-opted by tumors to suppress effective immune responses (Batlle and Massagué, 2019; Gigante et al., 2012).”
From Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies (2020) · cites this paper as Gigante et al., 2012
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Akira, S., & Takeda, K. (2004) · Nature reviews. Immunology · doi:10.1038/nri1391 · Cited by 8,312
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992 · cited 2×
“2010; 184: 6556 [114] Bettelli E, Carrier Y, Gao W, et al.”
BackgroundMyeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus
Shi, Y., & Massagué, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00432-x · Cited by 5,857
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393 · cited 2×
“Despite fluctuations in popularity over the 36 years since Burnet’s paper was published due to limiting direct experimental evidence [2], by 2003 accumulating new data proved that the immune system not only protects the host against tumor formation, but also edits tumor immunogenicity [3,4].”
BackgroundSmad-dependent and Smad-independent pathways in TGF-β family signalling
Derynck, R., & Zhang, Y. E. (2003) · Nature · doi:10.1038/nature02006 · Cited by 5,373
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., & Littman, D. R. (2006) · Cell · doi:10.1016/j.cell.2006.07.035 · Cited by 5,145
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y.-H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., et al. (2005) · Nature Immunology · doi:10.1038/ni1261 · Cited by 4,265 · cited 2×
“Th17 cells produce IL-17, which is a potent inflammatory cytokine that impacts a variety of cell types including fibroblasts, endothelial cells, and epithelial cells to induce the expression of additional inflammatory cytokines, such as IL-6, TNF, G-CSF, chemokines, and matrix metalloproteases, all of which coordinate…”
Background
Cited by
The roles of TGFβ in the tumour microenvironment
Pickup, M., Novitskiy, S., & Moses, H. L. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3603 · Cited by 917
Poniatowski, Ł. A., Wojdasiewicz, P., Gasik, R., & Szukiewicz, D. (2015) · Mediators of Inflammation · doi:10.1155/2015/137823 · Cited by 281
Krstić, J., Trivanović, D., Mojsilović, S., & Santibanez, J. F. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/654594 · Cited by 225
Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies
Roth, T. L., Li, P. J., Blaeschke, F., Nies, J. F., Apathy, R., Mowery, C., Yu, R., Nguyen, M. L. T., Lee, Y., Truong, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.039 · Cited by 186
Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy
Zhong, X., Zhang, H.-T., Zhu, Y., Liang, Y., Yuan, Z., Li, J., Li, X., Li, X., Jia, Y., Tian, H., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-1141-9 · Cited by 144
Metadata
- Authors
- Gigante, M., Gesualdo, L., & Ranieri, E.
- Affiliations
- University of Foggia (IT)
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-09-01
- Volume
- 18
- Issue
- 27
- Pages
- 4126-4134
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2055370220
- Cited by
- 45
- References
- 121
- Citations by year
- 2026: 2 · 2024: 3 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 5 · 2019: 7 · 2018: 4 · 2017: 6 · 2016: 2 · 2015: 4 · 2014: 1 · 2013: 5
- FWCI
- 1.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Pharmaceutical Design (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- TGF-beta, antitumor immunity, tumor surveillance, immunosuppression, tumor microenvironment, metastasis, cancer immunotherapy, immune evasion, carcinogenesis
- MeSH terms
- Animals, Humans, Immunity, Innate, Immunologic Surveillance, Neoplasm Metastasis, Neoplasms, Transforming Growth Factor beta, Disease Progression, Adaptive Immunity, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.